Concepedia

Target therapy for<i>BRAF</i>mutated anaplastic thyroid cancer: a clinical and molecular study

Tiago Silva, Ricardo Rodrigues, Ana Saramago, Carolina Pires, Miguel Rito, Mariana Horta, Carmo Martins, Valeriano Leite, Branca Cavaco

European Journal of Endocrinology · 2023 · 21 citations · 31 references

DOIFull text

Open access

Abstract

Our results show a significant real-world efficacy of Dabrafenib plus Trametinib in both survival and recurrence compared with standard treatment, with a good safety profile.

References

31

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

David M. Hyman, Igor Puzanov, Vivek Subbiah et al. · New England Journal of Medicine · 2015 · 1.7K citations · Full text

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

Iñigo Landa, Tihana Ibrahimpašić, Laura Boucai et al. · Journal of Clinical Investigation · 2016 · 1.2K citations · Full text

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Journal of Clinical Oncology · 2017 · 848 citations · Full text

, , +15

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Eric J. Sherman, Bruce Robinson et al. · New England Journal of Medicine · 2020 · 731 citations · Full text

MEK1 mutations confer resistance to MEK and B-RAF inhibition

Krishna G. Vijayendran, Marie Zipser, Allison M. Sawyer et al. · Proceedings of the National Academy of Sciences · 2009 · 628 citations · Full text